|Bid||2.1500 x 1300|
|Ask||2.2200 x 1300|
|Day's Range||2.0200 - 2.1800|
|52 Week Range||0.2000 - 4.3000|
|Beta (5Y Monthly)||0.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Companies at the forefront of coronavirus vaccine research have been a veritable gold mine for investors this year. For example, shares of Moderna (NASDAQ: MRNA) have gained a staggering 278% over the first seven months of 2020, while Novavax's (NASDAQ: NVAX) stock has posted a healthy 3,500% return on investment during this same period. While Heat Biologics (NASDAQ: HTBX) and Vaxart (NASDAQ: VXRT) have both made quantum leaps in terms of their market caps this year, there's a strong chance that each of these lesser-known COVID-19 vaccine stocks may soon be gearing up for another jaw-dropping move higher.
The latest analyst coverage could presage a bad day for Heat Biologics, Inc. (NASDAQ:HTBX), with the analysts making...
Heat Biologics (NASDAQ: HTBX), a prerevenue biotech, is off to a strong start today. Specifically, Heat announced that its COVID-19 vaccine candidate exhibited compelling evidence of immunogenicity (the ability to provoke a body's immune response) in a preclinical (animal) study. While Heat is well behind the leaders in the race to develop a COVID-19 vaccine, these positive preclinical data could open the door for a lucrative collaboration with a big-name pharma or perhaps a sizable government grant.